- UNITY Biotechnology Inc (NASDAQ:UBX) shares are skyrocketing after 12- and 18-week data from its Phase 2 BEHOLD study of UBX1325 for diabetic macular edema (DME).
- DME is a diabetic complication that affects the blood vessels in the back of your eye.
- At 18 weeks after a single UBX1325 injection, the mean change in BCVA of UBX1325-treated subjects was an increase of 6.1 ETDRS letters, representing an improvement of +5.0 ETDRS letters compared to sham-treated subjects.
- Related: UNITY Biotech Stock Jumps On Additional Data From UBX1325 Trial In Vascular Eye Disease.
- In addition, patients treated with UBX1325 maintained CST compared to sham-treated patients who demonstrated progressive worsening of CST (i.e., increased retinal thickness) through 18 weeks.
- UBX1325 demonstrated a favorable safety and tolerability profile.
- At 12 weeks, a single injection of UBX1325 had a mean improvement in BCVA of +4.7 ETDRS letters from baseline compared to +1.3 ETDRS letters in sham-treated patients.
- Patients treated with UBX1325 had a mean change in CST of -1.4 microns from baseline compared to +40.3 microns in sham-treated patients.
- Unity ended the June quarter with a cash balance of approximately $64.5 million, providing a runway through Q1 2023.
- Price Action: UBX shares are 118.80% at $1.86 during the premarket session on the last check Friday.
Benchmark Reiterates Buy on Westrock Coffee, Maintains $15 Price Target
Benchmark analyst Todd Brooks reiterates Westrock Coffee (NASDAQ:WEST) with a Buy and maintains $15 price target.
